I-Tirzepatide Lyophilized High Purity 99% Peptide Powder 60mg ngevial ​​nganye yesifo seswekile kunye nokuncipha komzimba

I-Tirzepatide Lyophilized Powder (60 mg)

I-Tirzepatide (LY3298176) yi-agonist yokuqala ye-dual-acting ejolise kwi-GIP (i-glucose-exhomekeke kwi-insulinotropic polypeptide) kunye ne-GLP-1 (i-glucagon-like peptide-1) receptors. Ifumene imvume ye-FDA yase-US ngoMeyi ka-2022 yonyango lwe-2 yeswekile yesifo seswekile (T2DM) njengenxalenye yokutya kunye nokuzilolonga.
Le mveliso inikezelwa njenge-60mg lyophilized (eyomileyo) engumgubo oyinyumba kwi-vials, ekufuneka ihlaziywe ngamanzi e-bacteriostatic ngaphambi kokulawulwa. Xa kuthelekiswa ne-single GLP-1 i-receptor agonists efana ne-semaglutide okanye i-dulaglutide, i-tirzepatide ibonisa ukusebenza kakuhle ekuphuculeni ukulawulwa kwe-glucose yegazi, ukuphucula ukuvakalelwa kwe-insulin, kunye nokuxhasa ukulahleka kwesisindo esibalulekileyo. Ezi zibonelelo zibangelwa yindlela yokusebenza ye-synergistic ye-receptors ezimbini.

IiNzuzo eziPhambili
Ulawulo lweGlycemic

• Ivuselela ukukhutshwa kwe-insulin ngendlela exhomekeke kwi-glucose
• Yehlisa ukukhutshwa kweglucagon, ngokufanelekileyo ukwehlisa amanqanaba eglucose yegazi
• Ilinganisa iziphumo ezidityanisiweyo ze-metabolic zazo zombini i-GIP kunye ne-GLP-1

Ulawulo lobunzima

• Ukukhuthaza ukuhlutha kunye nokunciphisa i-caloric intake
• Kubonakaliswe ukwehla okukhulu kunye nokugcinwa kobunzima kwizifundo zeklinikhi

Impilo yentliziyo

• Idatha yokuqala ibonisa ukunciphisa umngcipheko we-cardiovascular risk kwizigulane ezine-T2DM

Ukusetyenziswa kunye nomthamo

• I-Tirzepatide lyophilized powder (60 mg) kufuneka ihlaziywe ngamanzi e-bacteriostatic ngaphambi kokusetyenziswa. Ulawulo lwenziwa ngesitofu esingaphantsi kwesikhumba, ngokuqhelekileyo kanye ngeveki ngosuku olunye ngeveki.

Uhlobo lwesi-2 seswekile

• I-Dose yokuqala: 2.5 mg kanye ngeveki
• I-Titration: Yandisa rhoqo kwiiveki ezi-4 njengoko kunyanyezelwe
• (→ 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg → 20 mg → 30 mg → 45 mg → ukuya kuma-60 mg)
• Umthamo oqhelekileyo: 10-30 mg ngeveki
• Ubuninzi beDose: 60 mg ngeveki

Ukutyeba kakhulu / Ulawulo lobunzima

• I-Dose yokuqala: 2.5 mg kanye ngeveki
• I-Titration: Ukunyuka kwethamo ngokuthe ngcembe njengoko kunyanyezelwe
• (2.5 → 5 → 7.5 → 10 → 12.5 → 15 → 20 → 30 → 45 → 60 mg)
• Umthamo oqhelekileyo: 30-60 mg ngeveki
• Ubuninzi beDose: 60 mg ngeveki

Uthelekiso lwedosi ecetyiswayo

Phawula:Qinisekisa ukuba idosi nganye yangaphambili inyamezeleke kakuhle phambi kokunyuka.

Iimpendulo Ezinokuba Zibi

• Amathumbu: Isicaphucaphu, ukugabha, urhudo, kunye nokungakhululeki kwesisu (ngokuqhelekileyo ngexesha lokuqalisa)
• I-Hypoglycemia: Umngcipheko ophantsi ngokubanzi, kodwa unyukile xa udityaniswa namanye amayeza e-antidiabetic
• Iintshukumo zeNdawo yokutofa: Ububomvu, ukurhawuzelelwa, ukudumba, okanye iintlungu ezingephi kwindawo
• I-Pancreatitis: Inqabile kodwa inokwenzeka; esweni iintlungu eziqhubekayo zesisu
• Iziphumo zezintso: Ukuhlolwa kokusebenza kwezintso kunokufuneka kubantu abathile

Pharmacokinetics

• Isiqingatha sobomi: malunga neveki ye-1
• Ubungakanani bedosi: Ixhasa ulawulo olulula kanye ngeveki

Isishwankathelo
I-Tirzepatide i-60 mg i-lyophilized powder imele isizukulwana esilandelayo sonyango lwenkqubela phambili, ukudibanisa ulawulo olunamandla lwe-glycemic kunye nokusebenza kakuhle kokulahlekelwa kwesisindo kunye nokukhuselwa kwentliziyo.
Ngeshedyuli ye-titration kancinane (2.5 mg → ukuya kwi-60 mg), ivumela ukunyamezela okuphuculweyo kunye nokuguquguquka kunyango lomntu ngamnye. Ulawulo lwayo lweveki nganye luphucula ukuthotyelwa, okwenza kube yindlela entsha kunye nesebenzayo yokulawula uhlobo lwe-2 yeswekile kunye nokukhuluphala kwikliniki ephezulu kunye nezicwangciso zophando.